{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:55:25Z","timestamp":1784674525731,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,7,18]],"date-time":"2016-07-18T00:00:00Z","timestamp":1468800000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s00432-016-2209-1","type":"journal-article","created":{"date-parts":[[2016,7,18]],"date-time":"2016-07-18T16:34:21Z","timestamp":1468859661000},"page":"2041-2049","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany"],"prefix":"10.1007","volume":"142","author":[{"given":"Kathleen","family":"Jentsch-Ullrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja","family":"Zeremski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Wolleschak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2438-1955","authenticated-orcid":false,"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,18]]},"reference":[{"key":"2209_CR1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ajh.23160","volume":"87","author":"E Antonioli","year":"2012","unstructured":"Antonioli E, Guglielmelli P, Pieri L, Finazzi M, Rumi E, Martinelli V et al (2012) Hydroxyurea-related toxicity in 3,411 patients with Ph\u2019-negative MPN. Am J Hematol 87:552\u2013554","journal-title":"Am J Hematol"},{"key":"2209_CR2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405","journal-title":"Blood"},{"key":"2209_CR3","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1038\/bcj.2015.64","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T, Thiele J, Vannucchi AM, Tefferi A (2015) Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer J 5:e337","journal-title":"Blood Cancer J"},{"key":"2209_CR4","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","volume":"113","author":"G Barosi","year":"2009","unstructured":"Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC et al (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European leukemianet consensus conference. Blood 113:4829\u20134833","journal-title":"Blood"},{"key":"2209_CR5","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","volume":"148","author":"G Barosi","year":"2010","unstructured":"Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H et al (2010) A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European leukemianet (ELN) consensus process. Br J Haematol 148:961\u2013963","journal-title":"Br J Haematol"},{"key":"2209_CR6","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054\u20131061","journal-title":"Lancet"},{"key":"2209_CR7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.0954-6820.1962.tb07186.x","volume":"172","author":"E Chievitz","year":"1962","unstructured":"Chievitz E, Thiede T (1962) Complications and causes of death in polycythaemia vera. Acta Med Scand 172:513\u2013523","journal-title":"Acta Med Scand"},{"key":"2209_CR8","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1046\/j.1365-2141.2001.03161.x","volume":"115","author":"F Diehn","year":"2001","unstructured":"Diehn F, Tefferi A (2001) Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. Br J Haematol 115:619\u2013621","journal-title":"Br J Haematol"},{"key":"2209_CR9","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","volume":"371","author":"G Genovese","year":"2014","unstructured":"Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF et al (2014) Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371:2477\u20132487","journal-title":"N Engl J Med"},{"key":"2209_CR10","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","volume":"126","author":"H Gisslinger","year":"2015","unstructured":"Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA et al (2015) Ropeginterferon alfa-2b, a novel IFNalpha-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood 126:1762\u20131769","journal-title":"Blood"},{"key":"2209_CR11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","volume":"353","author":"CN Harrison","year":"2005","unstructured":"Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D et al (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353:33\u201345","journal-title":"N Engl J Med"},{"key":"2209_CR12","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG et al (2014) Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371:2488\u20132498","journal-title":"N Engl J Med"},{"key":"2209_CR13","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144\u20131148","journal-title":"Nature"},{"key":"2209_CR14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H et al (2016) Antithrombotic therapy for VTE disease: chest guideline and expert panel report. Chest 149:315\u2013352","journal-title":"Chest"},{"key":"2209_CR15","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779\u20131790","journal-title":"N Engl J Med"},{"key":"2209_CR16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"R Landolfi","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C et al (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350:114\u2013124","journal-title":"N Engl J Med"},{"key":"2209_CR17","unstructured":"Lengfelder E, Baerlocher GM, Gisslinger HMG and Petrides PE (2014) Polycythaemia vera (PV). Onkopedia-Leitlinie der Deutschen Gesellschaft f\u00fcr H\u00e4matologie und Onkologie (DGHO)"},{"key":"2209_CR18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387\u2013397","journal-title":"Cancer Cell"},{"key":"2209_CR19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D et al (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368:22\u201333","journal-title":"N Engl J Med"},{"key":"2209_CR20","doi-asserted-by":"crossref","unstructured":"Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S et al (2014) Impact of myeloproliferative neoplasms (mpns) on patients\u2019 overall health and productivity: results from the MPN landmark survey in the United States. Blood\u2014ASH annual meeting abstracts; Abstract 3183","DOI":"10.1182\/blood.V124.21.3183.3183"},{"key":"2209_CR21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","volume":"16","author":"R Mesa","year":"2016","unstructured":"Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S et al (2016) Myeloproliferative neoplasms (MPNs) have a significant impact on patients\u2019 overall health and productivity: the MPN landmark survey. BMC Cancer 16:167","journal-title":"BMC Cancer"},{"key":"2209_CR22","first-page":"1194","volume":"89","author":"P Mossuz","year":"2004","unstructured":"Mossuz P, Girodon F, Donnard M, Latger-Cannard V, Dobo I, Boiret N et al (2004) Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 89:1194\u20131198","journal-title":"Haematologica"},{"key":"2209_CR23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-016-0031-8","volume":"5","author":"S Parasuraman","year":"2015","unstructured":"Parasuraman S, DiBonaventura M, Reith K, Naim A, Concialdi K, Sarlis NJ (2015) Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review. Exp Hematol Oncol 5:3","journal-title":"Exp Hematol Oncol"},{"key":"2209_CR24","unstructured":"Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T et al (2016) Ruxolitinib proves superior to best available therapy in patients with polycythemia vera resistant to or intolerant of hydroxyurea without splenomegaly: results from response-2. Haematologica (EHA annual meeting abstracts)"},{"key":"2209_CR25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","volume":"118","author":"R Scherber","year":"2011","unstructured":"Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM et al (2011) The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 118:401\u2013408","journal-title":"Blood"},{"key":"2209_CR26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356:459\u2013468","journal-title":"N Engl J Med"},{"key":"2209_CR27","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F et al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27:1874\u20131881","journal-title":"Leukemia"},{"key":"2209_CR28","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood-2014-07-551929","volume":"124","author":"AM Vannucchi","year":"2014","unstructured":"Vannucchi AM (2014) How I treat polycythemia vera. Blood 124:3212\u20133220","journal-title":"Blood"},{"key":"2209_CR29","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F et al (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372:426\u2013435","journal-title":"N Engl J Med"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-016-2209-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-016-2209-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-016-2209-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T03:09:28Z","timestamp":1600916968000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-016-2209-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,18]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["2209"],"URL":"https:\/\/doi.org\/10.1007\/s00432-016-2209-1","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,18]]}}}